

line 19, after "endonucleases." insert --(SEQ ID NOS:17 through 44)--;

and

line 28, after "pAF100." insert --(SEQ ID NOS:45 through 50)--.

Page 10, line 21, delete "HR" and insert therefor --homologous recombination (HR)--.

Page 13, line 18, delete "SSA" and insert therefor --single-strand annealing (SSA)--.

Page 14, line 22, delete "a)" and insert therefor --a1)--.

Page 18, substitute the following for the last two lines:

--5' TAGGGATAA ↓ CAGGGTAAT 3' (SEQ ID NO:51)

3' ATCCC ↓ TATTGTCCCATTA 5' (SEQ ID NO:52)--.

Page 48, line 2, delete "'polybrain'" and insert therefor --polybrene (hexadimethrine bromide)--.

Page 72, line 3, delete "[11]" and insert therefor --[11B]--.

Page 72, line 23, delete "[13]" and insert therefor --[13B]--.

Page 72, line 27, delete "[12]" and insert therefor --[12B]--.

Page 80, line 14, delete "[29]" and insert therefor --[29B]--.

Page 91, line 24, delete "Varmus, H. and Brown, P. 1989. Retroviruses" and insert therefor --Varmus, H. and Brown, P., Retroviruses *in* Mobile DNA, 58-108 (Douglas E. Berg and Martha H. Howe eds., 1989).--.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000

Serial No. 09/244,130
Atty. Docket No. 3495.0111-10

After making the above amendments, please move pages 50-58 and insert these pages after page 88 and before page 89 of the application. Then please renumber the pages as follows:

Renumber pages 50-58 as pages 80-88, respectively; and renumber pages 59-88 as pages 50-79, respectively.

After page 93, and before page 94, please insert the attached pages titled "SEQUENCE LISTING".

On pages 89-93, renumber references "1" through "37" to read --1B-- through --37B--.

IN THE CLAIMS:

Please cancel claims 1 and 15.

Please add the following new claims:

- A₂
- 23. A transgenic mouse comprising a nucleotide sequence encoding I-SceI.
24. A transgenic mouse comprising a recombinant cell, wherein said cell comprises a nucleotide sequence encoding I-SceI.
25. The mouse of claim 24, wherein the nucleotide sequence is in a plasmid.
26. The mouse of claim 25, wherein the plasmid is pRSV I-SceI or pCMV I-SceI.
27. A transgenic mouse comprising a nucleotide sequence, wherein said nucleotide sequence comprises an I-SceI site.